Population-based cohort study of warfarin-treated patients with atrial fibrillation: Incidence of cardiovascular and bleeding outcomes

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Gallagher, Arlene M ^a,b   Van Staa, Tjeerd P ^a,b   Murray Thomas, Tarita ^a   Schoof, Nils ^c   Clemens, Andreas ^c,d   Ackermann, Diana ^c   Bartels, Dorothee B ^c,e  

^a Clinical Practice Research Datalink   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; FEMALE; HEMORRHAGE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; THROMBOSIS; WARFARIN; YOUNG ADULT;

EID: 84894185585     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003839     Document Type: Article

References (28)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC): developed with the special contribution of the European Heart Rhythm Association (EHRA), endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2369-429.
2. Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W investigators benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
4. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 2011;123:2094-100.
5. Williams T, van staa T, Puri S, et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012;3:89-99.
6. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
7. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
8. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860-5.
9. Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008;156:57-64. (Pubitemid 351877101)
10. Lewis JD, Brensinger C. Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 2004;13:437-41. (Pubitemid 38996854)
11. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-41.
12. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
13. Frost L, Andersen LV, Vestergaard P, et al. Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: national cohort study in Denmark, 1980-2002. Neuroepidemiology 2006;26:212-19.
14. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967-75.
15. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92.
16. Ruigomez A, Johansson S, Wallander MA, et al. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. Int J Cardiol 2009;136:186-92.
17. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007;120:700-5. (Pubitemid 47176507)
18. Gallagher AM, Puri S, van Staa TP. Linkage of the General Practice Research Database (GPRD) with Other Data Sources [528]. Poster presentation at 27th International Conference of Pharmacoepidemiology, August 16th 2011, Chicago, IL, USA.
19. Parkinson J, Davis S, van Staa TP. The General Practice Research (GPRD) Database: now and the future. In: Mann R. Pharmacovigilance editor. 2nd edn. John Wiley & Sons, 2007:341-8.
20. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-68.
21. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013;34:1041-9.
22. Ruigómez A, Johansson S, Wallander M-A, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002;55:358-63. (Pubitemid 34245363)
23. Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001;12:682-9. (Pubitemid 33134531)
24. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-20. (Pubitemid 28226280)
25. Stürmer T, Rothman KJ, Avorn J, et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol 2010;172:843-54.
26. Silberman G, Droitcour JA, Scullin EW. Cross design synthesis: a new strategy for medical effectiveness research. Darby, USA: Diane Publishing Co, 1992.
27. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
28. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.